Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (MANAGE)
|ClinicalTrials.gov Identifier: NCT01873417|
Recruitment Status : Completed
First Posted : June 10, 2013
Results First Posted : November 11, 2014
Last Update Posted : March 21, 2017
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal (GI)-related events reported by participants with relapsing forms of multiple sclerosis (MS) initiating therapy with dimethyl fumarate (DMF) in the clinical practice setting.
The secondary objectives of this study are as follows:
- To evaluate GI-related events requiring symptomatic therapy and the role of those therapies over time in participants with relapsing forms of MS initiating therapy with DMF in the clinical practice setting.
- To evaluate GI-related events that lead to DMF discontinuation after the use of symptomatic therapy in participants with relapsing forms of MS initiating therapy with DMF in the clinical practice setting.
|Condition or disease||Intervention/treatment||Phase|
|Relapsing Forms of Multiple Sclerosis||Drug: BG00012 (DMF)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||237 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||November 2013|
Experimental: Dimethyl Fumarate
120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
Drug: BG00012 (DMF)
- Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS) [ Time Frame: 12 Weeks ]Severity of GI-related events in DMF-treated participants using the MOGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
- Worst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale [ Time Frame: 12 Weeks ]Severity of GI-related events in DMF-treated participants using the MAGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
- Percentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy [ Time Frame: 12 Weeks ]Percentage of participants reporting GI symptoms on the MOGISS, by those who utilized symptomatic therapy.
- Duration of GI-related Episodes in DMF-treated Participants [ Time Frame: 12 Weeks ]In participants who took symptomatic therapy, the median duration of acute GI episodes (in hours) was summarized for the overall treatment period, by symptom (nausea, diarrhea, lower abdominal pain, upper abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence). Table only includes the symptom duration for those symptoms with start and stop times entered in the eDiary (evaluable GI episodes), based on the MAGISS.
- Percentage of DMF-treated Participants Who Required GI Symptomatic Therapy [ Time Frame: 12 Weeks ]Percentage of participants reporting that they required GI symptomatic therapy, based on the MOGISS.
- Participants' Use of Symptomatic Therapy, by Type and Category [ Time Frame: 12 Weeks ]The symptomatic therapies used by DMF-treated participants were self-reported by type and category. Each participant may have taken more than one symptomatic therapy type but was counted only once within each therapy category. Acetylsalicylic acid (ASA) is abbreviated in the table.
- Summary of Use and Days on Symptomatic Therapy, by Category [ Time Frame: 12 Weeks ]The total duration (in days) of use of each symptomatic therapy by participants as a result of GI symptoms experienced by DMF-treated participants is presented. If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in the 'All Therapies' category.
- Number of DMF-treated Participants Who Discontinued DMF Due to GI-related Events Requiring Symptomatic Therapy [ Time Frame: 12 Weeks ]The last symptomatic therapy prior to last dose of study medication was used to summarize the number of participants who discontinued DMF due to GI-related events. Participants may have taken more than one symptomatic therapy but are counted only once in the 'All Therapies' category.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01873417
|United States, Alabama|
|Cullman, Alabama, United States, 35058|
|United States, Arizona|
|Gilbert, Arizona, United States, 85234|
|Scottsdale, Arizona, United States, 85258|
|United States, California|
|Fullerton, California, United States, 92835|
|Newport Beach, California, United States, 92663|
|Pasadena, California, United States, 91105|
|United States, Colorado|
|Englewood, Colorado, United States, 80113|
|Fort Collins, Colorado, United States, 80528|
|United States, Connecticut|
|Danbury, Connecticut, United States, 06810|
|United States, Florida|
|Maitland, Florida, United States, 32751|
|Naples, Florida, United States, 34102|
|North Palm Beach, Florida, United States, 33408|
|Port Charlotte, Florida, United States, 33952|
|Sarasota, Florida, United States, 34239|
|St. Petersburg, Florida, United States, 33713|
|Tampa, Florida, United States, 33609|
|Tampa, Florida, United States, 33612|
|United States, Georgia|
|Atlanta, Georgia, United States, 30327|
|United States, Indiana|
|Indianapolis, Indiana, United States, 46256|
|United States, Massachusetts|
|Milford, Massachusetts, United States, 01757|
|United States, Minnesota|
|Golden Valley, Minnesota, United States, 55422|
|United States, New York|
|Patchogue, New York, United States, 11772|
|United States, North Carolina|
|Charlotte, North Carolina, United States, 28204|
|Greensboro, North Carolina, United States, 27405|
|High Point, North Carolina, United States, 27262|
|United States, North Dakota|
|Fargo, North Dakota, United States, 58103|
|United States, Oregon|
|Portland, Oregon, United States, 97225|
|United States, Pennsylvania|
|Monroeville, Pennsylvania, United States, 15215|
|United States, Tennessee|
|Cordova, Tennessee, United States, 38018|
|Franklin, Tennessee, United States, 37064|
|Knoxville, Tennessee, United States, 37934|
|United States, Texas|
|Round Rock, Texas, United States, 78681|
|United States, Utah|
|Salt Lake City, Utah, United States, 84103|
|United States, Virginia|
|Richmond, Virginia, United States, 23298|
|Roanoke, Virginia, United States, 24018|
|United States, Washington|
|Tacoma, Washington, United States, 98405|
|United States, Wisconsin|
|Milwaukee, Wisconsin, United States, 53215|
|Study Director:||Medical Director||Biogen|